Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242164 | 0.89 | THRB (0.40) | THRBALDH1A1DRD2HTR2AHRH1 | |
| SCHEMBL15150212 | 0.80 | ALDH1A1 (0.41) | ALDH1A1APOBEC3GGAAGLAKMT2A | |
| SCHEMBL20093073 | 0.80 | ALDH1A1 (0.37) | ALDH1A1APOBEC3GGLAKMT2ATDP1 | |
| SCHEMBL24618681 | 0.80 | ALDH1A1 (0.37) | ALDH1A1APOBEC3GNAMPTCYP2D6CYP2C9 | |
| SCHEMBL294897 | 0.79 | ALDH1A1 (0.41) | THRBALDH1A1DRD2HTR2AHRH1 | |
| SCHEMBL15134216 | 0.78 | DRD2 (0.48) | THRBALDH1A1DRD2HTR2AHRH1 | |
| SCHEMBL18997768 | 0.77 | HTR4 (0.35) | ALDH1A1APOBEC3GTDP1CYP2D6CYP2C9 | |
| SCHEMBL1061779 | 0.77 | HTR2A (0.40) | THRBALDH1A1DRD2HTR2AHRH1 | |
| SCHEMBL12954786 | 0.77 | THRB (0.40) | THRBALDH1A1DRD2HTR2AHRH1 | |
| SCHEMBL292558 | 0.77 | NPC1 (0.40) | THRBALDH1A1APOBEC3GDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646410-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB Science (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024146923-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB SCIENCE (FR) | 2024-07-11 | — | — | WO | disclosed |
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4308563-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321055-A | Modulators of STING (interferon gene stimulators) | 辉瑞公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20220306641-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2022195462-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | THRB 2230/4885ALDH1A1 4771/4885APOBEC3G 427/4885 |
| US-20220306641-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | THRB 2230/4885ALDH1A1 4771/4885APOBEC3G 427/4885 |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | THRB 2230/4885ALDH1A1 4771/4885APOBEC3G 427/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | THRB 1733/4885ALDH1A1 2765/4885APOBEC3G 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.